shigella conjugate vaccine

This shigella conjugate vaccine is a preclinical-stage candidate developed by Techinvention Lifecare for the prevention of shigellosis. The vaccine utilizes a conjugation strategy, linking *Shigella* surface antigens—typically the O-specific polysaccharide (OSP) of the lipopolysaccharide—to a carrier protein. This approach is designed to overcome the poor immunogenicity of pure polysaccharides, particularly in infants and young children, by inducing a T-cell dependent immune response. The goal is to provide broad protection against the most prevalent *Shigella* serotypes responsible for severe diarrhea and dysentery globally.

Other names

Techinvention Shigella vaccine